Delcath Systems Presents New Data on Percutaneous Hepatic Perfusion with Melphalan at ESMO Breast Cancer 2026
Delcath Systems, Inc. has announced the presentation of new data from a retrospective analysis on the use of percutaneous hepatic perfusion with melphalan (M-PHP) for treating liver-dominant metastatic breast cancer. This data was shared at the ESMO Breast Cancer Congress 2026, demonstrating the effectiveness of the CHEMOSAT® Hepatic Delivery System.
QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis by independent investigators on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT® Hepatic Delivery System was presented today at the ESMO Breast Cancer Congress 2026. Presentation details Congress: ESMO Breast Cancer Congress 2026 Dat